1. Search Result
Search Result
Results for "

Binding site

" in MedChemExpress (MCE) Product Catalog:

459

Inhibitors & Agonists

7

Screening Libraries

8

Fluorescent Dye

3

Biochemical Assay Reagents

58

Peptides

1

MCE Kits

2

Inhibitory Antibodies

25

Natural
Products

27

Isotope-Labeled Compounds

4

Click Chemistry

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-157508
    VCP Activator 1
    1 Publications Verification

    p97 Others
    VCP Activator 1 is a VCP activator that dose-dependently stimulates VCP ATPase activity. VCP Activator 1 binds an allosteric pocket near the C-terminus. In addition, VCP Activator 1 binding site can also be occupied by a phenylalanine residue in the VCP C-terminal tail .
    VCP Activator 1
  • HY-162089

    Microtubule/Tubulin Apoptosis Cancer
    MY-1442 (I-3) is a microtubulin polymerization inhibitor. MY-875 inhibits tubulin polymerization by targeting colchicine binding sites. MY-1442 has anticancer activity. MY-1442 can induce apoptosis of MGC-803 cells and inhibit cell migration .
    MY-1442
  • HY-150761

    Microtubule/Tubulin Apoptosis Cancer
    MY-875 is a competitive microtubulin polymerization inhibitor with an IC50 value of 0.92 μM. MY-875 inhibits microtubulin polymerization by targeting colchicine binding sites and activates the Hippo pathway. MY-875 induces apoptosis and has anticancer activity .
    MY-875
  • HY-149414

    Microtubule/Tubulin Apoptosis ERK TGF-beta/Smad Cancer
    MY-673 is a colchicine binding site inhibitor (CBSI), that inhibits tubulin polymerization. MY-673 inhibits the ERK signaling pathway, which in turn affects SMAD4 protein expression levels in the TGF-β/SMAD pathway. MY-673 inhibited cell proliferation, migration and induced apoptosis in vivo and in vitro .
    MY-673
  • HY-18698

    iGluR Neurological Disease
    L-701324 is a potent, orally active NMDA receptor antagonist that antagonizes the activity of the NMDA receptor by blocking its glycine B binding site. L-701324 binds with high affinity to rat brain membranes (IC50=2 nM). L-701324 has antidepressant activity .
    L-701324
  • HY-161800

    Aminoacyl-tRNA Synthetase Infection
    Aminoacyl tRNA synthetase-IN-3 (compound 36K3) is an inhibitor of lysine tRNA synthetase (PfLysRS) from Plasmodium falciparum (IC50=59.2 nM), which inhibits the activity of PfLysRS by occupying the ATP binding site and L-lysine binding site of PfLysRS. Aminoacyl tRNA synthetase-IN-3 can be used in the development of antimalarial drugs .
    Aminoacyl tRNA synthetase-IN-3
  • HY-149020

    Microtubule/Tubulin Apoptosis Cancer
    Tubulin polymerization-IN-26 (compound 12h) can inhibit the polymerization of microtubulin by binding to the colchicine binding site of microtubulin with an IC50 value of 4.64 μM. Tubulin polymerization-IN-26 can induce apoptosis and inhibit cell metastasis or migration, and can be used as a potential compound for lung cancer research .
    Tubulin polymerization-IN-26
  • HY-19111

    TIBO-R 82150

    HIV Reverse Transcriptase Infection
    R-82150 (TIBO-R 82150) is an HIV-1 reverse transcriptase inhibitor that blocks the reverse transcription of viral RNA by binding to the non-substrate binding site of reverse transcriptase, thereby inhibiting viral replication. R-82150 does not inhibit the replication of HIV-2, other RNA viruses, and DNA viruses .
    R-82150
  • HY-D1608

    Calcium Channel Others
    BODIPY FL Thapsigargin is a potent green fluorescent dye. BODIPY FL Thapsigargin inhibits intracellular SERCA-type Ca2+ pumps present in the sarcoplasmic/endoplasmic reticulum. BODIPY FL Thapsigargin used for investigation of thapsigargin binding sites in live cells .
    BODIPY FL Thapsigargin
  • HY-147736

    GABA Receptor Neurological Disease
    GABAA receptor agonist 2 (compound 4c) is a potent GABAA receptor agonist. GABAA receptor agonist 2 shows anti-depression activities in classical mouse models of depression of FST and TST. GABAA receptor agonist 2 binds at the GABA binding site of GABAA receptor in order to produce GABAergic effects. GABAA receptor agonist 2 has the potential for the research of depression .
    GABAA receptor agonist 2
  • HY-147947

    Microtubule/Tubulin Cancer
    Tubulin polymerization-IN-30 (compound 6e) is a potent Tubulin polymerization inhibitor. Tubulin polymerization-IN-30 is a colchicine binding site inhibitor. Tubulin polymerization-IN-30 can disrupt intracellular microtubule organization, arrest cell cycle at the G2/M phase. Tubulin polymerization-IN-30 exhibits the high potency against the cancer cell lines including SGC-7901, A549 and HeLa, with IC50 values of 2.16, 2.21, and 0.403 μM .
    Tubulin polymerization-IN-30
  • HY-101344

    5-HT Receptor Neurological Disease
    Cyanopindolol fumarate is a 5-HT receptor antagonist .
    Cyanopindolol fumarate
  • HY-162659

    Adrenergic Receptor Others
    β2AR ligand 1 (Compound 4) is a homobivalent bitopic ligand for β2 adrenergic receptor (β2AR) on the orthosteric binding site (OBS) and the metastable binding sites (MBS) .
    β2AR ligand 1
  • HY-P5343

    p53 Consensus Binding sequence

    MDM-2/p53 Others
    p53 CBS (p53 Consensus binding sequence) is a biological active peptide. (p53 consensus DNA binding site)
    p53 CBS
  • HY-N15270

    Secantioquine

    Dopamine Receptor Others
    S-Secoantioquine (Secantioquine) is a bisbenzylisoquinoline alkaloid secoderivative. In the rat striate membrane experiment, S-Secoantioquine shows weak displacement activity on 3H-SCH 23390 binding site, and certain displacement activity on 3H-raclopride binding site .
    S-Secoantioquine
  • HY-N7652

    Bacterial Infection Inflammation/Immunology
    Terminolic acid is a pentacyclic triterpenoid glucoside isolated from Combretum racemosum. Terminolic acid can inhibit the pro-inflammatory cytokines by binding to receptor active site of IL-1β and IL-6, and enhance anti-inflammatory cytokines by binding to IL-4 receptor binding sites. Terminolic acid also exhibits moderate antibacterial activity .
    Terminolic acid
  • HY-N7437

    Opioid Receptor DNA/RNA Synthesis Neurological Disease Inflammation/Immunology
    Akuammidine, isolated from the seeds of Picralima nitida, shows a preference for μ-opioid binding sites with Ki values of 0.6, 2.4 and 8.6 μM at μ-, σ- and κ-opioid binding sites, respectively. Akuammidine possesses anti-inflammatory and anti-asthmatic properties .
    Akuammidine
  • HY-118168

    Galosfen

    Topoisomerase Others
    A9387 is an inhibitor of the Tn3 Resolvase, which promotes site-specific recombination reactions between two directly repeated recombination sites. Several inhibitors have been isolated that inhibit this event. A9387 inhibits the binding of resolvase to the res site .
    A 9387
  • HY-107578

    Macbecin I; NSC 330499

    HSP Cancer
    Macbecin is a stable HSP90 inhibitor by binding to the ATP-binding site with an IC50 of 2 μM and a Kd of 0.24 μM. Macbecin exhibits antitumor and cytocidal activities .
    Macbecin
  • HY-126054

    Topoisomerase Others
    A1062 is an inhibitor for Tn3 encoded resolvase with IC50 in micromolar level. A1062 suppresses the binding of resolvase proteins to res sites, and blocks resolvase-induced site-specific recombination .
    A1062
  • HY-103172

    nAChR Metabolic Disease
    8-Aminoadenine is an adenine receptor ligand, with a Ki of 6.51 μM at the human binding site .
    8-Aminoadenine
  • HY-D1030

    Fluorescent Dye Inflammation/Immunology
    Fluorescein Biotin is used as an alternative to radioactive biotin for detecting and quantitating biotin-binding sites by either fluorescence or absorbance; the the fluorescence or absorbance of Fluorescein Biotin is quenched, upon binding to avidin or streptavidin.
    Fluorescein Biotin
  • HY-D0987

    Calmodulin Others
    Stains-All, a cationic carbocyanine dye, is a convenient probe to study the structural features of the individual calcium-binding sites of calmodulin (CaM) and related calcium-binding proteins (CaBP) .
    Stains-All
  • HY-18601
    (±)-BI-D
    5 Publications Verification

    HIV HIV Integrase Infection
    (±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.
    (±)-BI-D
  • HY-100143

    CGS 10746

    Dopamine Receptor Neurological Disease
    Pentiapine (CGS 10746) is a dopamine release inhibitor without binding to synaptic dopamine receptor sites .
    Pentiapine
  • HY-170864

    Microtubule/Tubulin Neurological Disease Cancer
    BKS3031A is the inhibitor for αβ-tubulin that binds to the colchicine binding site, and inhibits the microtubule assembly dynamics .
    BKS3031A
  • HY-100998

    iGluR Neurological Disease
    Metaphit is a specific PCPantagonist and site-directed acylating agent of the [3H]phencyclidine binding site in rat brain homogenates . Metaphit prevents PCP-induced locomotor behavior through presynaptic mechanisms .
    Metaphit
  • HY-122430

    Antibiotic Others
    Rosaramicin is a macrolide antibiotic that binds to the ribosomal P site and produces a synergistic effect with puromycin. This synergistic effect may be related to the interaction between the A and P sites. At the same time, its binding activity is affected by multiple substances.
    Rosaramicin
  • HY-129090

    GABA Receptor Neurological Disease
    CGS-​9895 is a GABA antagonist that acts via the benzodiazepine binding site of ag containing GABA receptors .
    CGS-​9895
  • HY-10830A

    Estrogen Receptor/ERR Cancer
    PBPE hydrochloride is a derivative of tamoxifen (HY-13757A) and a selective ligand for the anti-estrogen binding site (AEBS), the binding affinities (Ki) of PBPE hydrochloride and MBPE to AEBS are 8.79 and 17.57 nM, respectively .
    PBPE hydrochloride
  • HY-120524

    iGluR Neurological Disease
    CGP 31358 is an anticonvulsant agent that binds to a site on the NMDA receptor complex that is coupled to both the transmitter recognition site and to the channel domain. CGP 31358 inhibits the binding of L-Glutamate to the NMDA receptor complex with an IC50 of 53 μM .
    CGP 31358
  • HY-P1741
    Fibrinogen-Binding Peptide
    1 Publications Verification

    Thrombin Cardiovascular Disease
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin .
    Fibrinogen-Binding Peptide
  • HY-100998A

    iGluR Neurological Disease
    Metaphit methylsulfate is a specific PCP antagonist and site-directed acylating agent of the [3H]phencyclidine binding site in rat brain homogenates. Metaphit methylsulfate prevents PCP-induced locomotor behavior through presynaptic mechanisms .
    Metaphit methylsulfate
  • HY-119105

    GABA Receptor Neurological Disease
    LY81067, a diaryltriazine, effectively protects against Pentylenetetrazole- and Picrotoxin-induced convulsions in mice. LY81067 exerts its anticonvulsant effects by binding to or near Picrotoxin (HY-101391) binding sites .
    LY81067
  • HY-NP009

    Biochemical Assay Reagents Others
    α-Lactalbumin is a Ca 2+-binding protein. α-Lactalbumin has a single strong Ca 2+-binding site and for this reason it frequently serves as a simple model Ca 2+-binding protein. α-Lactalbumin is a component of lactose synthase, an enzyme system, which consists of galactosyltransferase (GT) and α-Lactalbumin .
    α-Lactalbumin
  • HY-163097

    iGluR Neurological Disease
    ZCAN262 (compound 6 ) is an AMPA modulator. ZCAN262 prevents AMPA-mediated excitotoxicity by targeting an allosteric binding site .
    ZCAN262
  • HY-P1507

    Integrin Cardiovascular Disease
    Fibrinogen Binding Inhibitor Peptide is a dodecapeptide (HHLGGAKQAGDV, H12), which is a fibrinogen γ-chain carboxy-terminal sequence (γ400-411). Fibrinogen Binding Inhibitor Peptide is a specific binding site of the ligand for activated glycoprotein (GP) IIb/IIIa.
    Fibrinogen Binding Inhibitor Peptide
  • HY-A0005
    Clofarabine
    5+ Cited Publications

    Nucleoside Antimetabolite/Analog Autophagy Apoptosis Metabolic Disease Cancer
    Clofarabine, a nucleoside analogue for research of cancer, is a potent inhibitor of ribonucleotide reductase (IC50=65 nM) by binding to the allosteric site on the regulatory subunit .
    Clofarabine
  • HY-163746

    Cholinesterase (ChE) Neurological Disease
    BuChE-IN-11 (Compound 3b-1) is an selective BuChE inhibitor with an IC50 of 0.44 μM for hBuChE. BuChE-IN-11 has high blood-brain barrier permeability and exhibits strong antioxidant activity due to its free radical scavenging properties. BuChE-IN-11 interacts with the choline binding site, acetyl binding site, and peripheral anionic site, exhibiting submicromolar BuChE inhibitory activity and preventing β-amyloid (Aβ) self-aggregation. BuChE-IN-11 holds promise for research in the field of Alzheimer's disease .
    BuChE-IN-11
  • HY-16307
    MB05032
    5 Publications Verification

    FBPase Metabolic Disease
    MB05032 is a special and efficacious gluconeogenesis inhibitor targeted the AMP binding site of fructose 1,6-bisphosphatase (FBPase) with an IC50 value of 16 nM.
    MB05032
  • HY-P2463

    Arp2/3 Complex Inflammation/Immunology
    Fequesetide, a peptide segment, is the active site within the protein thymosin β4 responsible for actin binding, cell migration and wound healing .
    Fequesetide
  • HY-B0149S

    Isotope-Labeled Compounds Cardiovascular Disease
    Tranexamic acid-d2 is the deuterium labeled Tranexamic acid. Tranexamic acid (Transamin) is an antifibrinolytic for blocking lysine-binding sites of plasmin and elastase-derived plasminogen fragments.
    Tranexamic acid-d2
  • HY-N3269

    Others Others
    Methyl p-hydroxyphenyllactate (MeHPLA) is an important cell growth-regulating agent which binds to nuclear type II binding sites in normal and malignant cells .
    Methyl p-hydroxyphenyllactate
  • HY-119453

    Dihydroorotate Dehydrogenase Metabolic Disease Inflammation/Immunology
    Oxycinchophen exhibits anti-inflammatory and uricosuric activity. Oxycinchophen displaces urate from albumin, exhibits high affinity for the DNSA-binding site on the albumin molecule .
    Oxycinchophen
  • HY-168006

    p97 ATP Synthase Cancer
    NSC819701 is a triazole inhibitor of the p97 ATPase. NSC819701 inhibits the activity of p97 ATPase by binding to a specific site of p97 .
    NSC819701
  • HY-B0115
    Pizotifen
    2 Publications Verification

    Pizotyline; BC-105

    5-HT Receptor Neurological Disease
    Pizotifen (Pizotyline) is a potent 5-HT2 receptor antagonist, with a high affinity for 5-HT1C binding site.
    Pizotifen
  • HY-118251

    Antifolate Dihydrofolate reductase (DHFR) Cancer
    PD130883 is an antifolate DHFR inhibitor that directly inhibits thymidylate synthase at the 5,10-methylenetetrahydrofolate binding site, reducing the net conversion of tetrahydrofolate cofactor to dihydrofolate.
    PD130883
  • HY-111007

    HSP Cancer
    CH5015765 is an orally available Hsp90 inhibitor bound to the N-terminal ATP binding site. CH5015765 plays an important role in cancer research .
    CH5015765
  • HY-120788

    Monoamine Transporter Others
    VMAT2-IN-4 (compound 11) is a vesicular monoamine transporter-2 (VMAT2) inhibitor. VMAT2-IN-4 inhibits [ 3H]-DTBZ binding (Ki = 560 nM). VMAT2-IN-4 inhibits [ 3H]-DA (Ki = 45 nM) from entering vesicles and being taken up by cells. VMAT2-IN-4 can be used in methamphetamine addiction research .
    VMAT2-IN-4
  • HY-146801

    PDHK Metabolic Disease Cancer
    PDHK-IN-3 (compound 7) is a potent PDHK (pyruvate dehydrogenase kinase) inhibitor, with IC50 values of 0.21 and 1.54 μM for PDHK2 and PDHK4, respectively .
    PDHK-IN-3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: